US Patent

US8173158 — Methods of treating gastrointestinal disorders independent of the intake of food

Method of Use · Assigned to Takeda Pharmaceuticals USA Inc · Expires 2030-03-17 · 4y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating gastrointestinal disorders by administering a pharmaceutical composition to a patient, regardless of when they eat.

USPTO Abstract

The present invention relates to a method of treating a gastrointestinal disorder by administering to a patient in need of treatment thereof a pharmaceutical composition, wherein said pharmaceutical composition can be administered to the patient independent of the intake of food.

Drugs covered by this patent

Dexilant (DEXLANSOPRAZOLE) · Takeda

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-951`	—	Dexilant
`U-951`	—	Dexilant

Patent Metadata

Patent number: US8173158
Jurisdiction: US
Classification: Method of Use
Expires: 2030-03-17
Drug substance claim: No
Drug product claim: No
Assignee: Takeda Pharmaceuticals USA Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.